KBC Group NV Grows Stock Position in Elanco Animal Health Incorporated (NYSE:ELAN)

KBC Group NV increased its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 264.9% in the 4th quarter, Holdings Channel reports. The firm owned 323,502 shares of the company’s stock after purchasing an additional 234,840 shares during the period. KBC Group NV’s holdings in Elanco Animal Health were worth $3,918,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in ELAN. Geode Capital Management LLC boosted its holdings in shares of Elanco Animal Health by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock worth $115,623,000 after purchasing an additional 65,303 shares during the last quarter. Atom Investors LP boosted its stake in Elanco Animal Health by 310.3% during the third quarter. Atom Investors LP now owns 345,855 shares of the company’s stock worth $5,081,000 after buying an additional 261,559 shares during the last quarter. Harbor Capital Advisors Inc. grew its holdings in Elanco Animal Health by 24.0% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock valued at $13,135,000 after buying an additional 209,734 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Elanco Animal Health by 19.2% in the 3rd quarter. Wellington Management Group LLP now owns 4,007,805 shares of the company’s stock worth $58,875,000 after acquiring an additional 646,522 shares during the last quarter. Finally, Franklin Resources Inc. raised its holdings in shares of Elanco Animal Health by 14.0% during the 3rd quarter. Franklin Resources Inc. now owns 372,230 shares of the company’s stock worth $5,349,000 after acquiring an additional 45,795 shares during the period. 97.48% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on ELAN shares. Morgan Stanley dropped their price objective on shares of Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating for the company in a report on Wednesday. Stifel Nicolaus cut their price target on shares of Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd. UBS Group assumed coverage on Elanco Animal Health in a research note on Monday, December 9th. They set a “buy” rating and a $18.00 target price for the company. Finally, Barclays increased their price target on Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $16.29.

Elanco Animal Health Trading Down 3.5 %

Shares of ELAN stock opened at $12.03 on Friday. The company has a 50 day moving average price of $12.19 and a 200 day moving average price of $13.24. The stock has a market capitalization of $5.95 billion, a P/E ratio of 30.08, a price-to-earnings-growth ratio of 2.76 and a beta of 1.41. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. Elanco Animal Health Incorporated has a fifty-two week low of $11.11 and a fifty-two week high of $18.80.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.01. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter last year, the business posted $0.18 EPS. The business’s quarterly revenue was down 3.6% compared to the same quarter last year. Equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.